Search Medical Condition
Please enter condition
Please choose location from dropdown

Lomme, France Clinical Trials

A listing of Lomme, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (568) clinical trials

Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder

Inclusions are performed by any previously-labeled baclofen-prescribing physician in the Hauts-de-France or Normandie French regions. INITIAL ASSESSMENT PHONE CALLS In the 15 days following the inclusion, participants will receive two successive phone calls. The first call will be performed by a physician investigator of the study who will: re-explain the ...

Phase

3.36 miles

Learn More »

Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE).

Randomized, double blind study enrolling 200 adults undergoing thoracotomy. Patients receive either 75 mg hydroxyzine before surgery and placebo 3 times daily for 10 days or 1200 mg gabapentin before surgery continued for 10 days. All patients receive also a thoracic epidural analgesia. Assessment of chronic pain at 3 month ...

Phase

3.36 miles

Learn More »

Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas

Adrenal incidentalomas are unsuspected adrenal masses found during abdominal imaging. With the widespread use of computed tomography and MRI, adrenal incidentalomas are found in approximately 2% of patients. In an endocrinology setting, the majority of these masses are benign adenomas of the adrenal cortex. Approximately 10% of these adenomas display ...

Phase N/A

3.36 miles

Learn More »

Therapeutic Nipple Sparing Mastectomy.

This is a phase III, multicentric, single arm study with a sequential design using the exact conditional Poisson test. The primary objective of this prospective study is to evaluate whether selected breast carcinoma patients could be treated with nipple sparing mastectomy (NSM) with an acceptable low local recurrence rates. 450 ...

Phase

3.36 miles

Learn More »

Bortezomib in Rejection of Kidney Transplants

Chronic active antibody-mediated rejection (AMR) is considered as a main cause of late allograft losses in kidney transplant recipients. It is due to the occurrence of de novo donor-specific anti-HLA antibodies (DSA), i.e. antibodies synthetized by the recipient after transplantation against its transplant. There is currently to efficient treatment. The ...

Phase

3.36 miles

Learn More »

Neuromuscular-Blocking Agents and Hypoxemia During Intubation in Infants (ROC-HYPOX)

The prevention of the occurrence of respiratory events is a constant concern in pediatric anesthesia, as these represent the main cause of the anesthesic mortality. These events occur partly during induction of anesthesia and are all the more frequent as the child is young. The French recommendations do not propose ...

Phase

3.36 miles

Learn More »

The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study

Venous thromboembolism (VTE) is a frequent condition, affecting 1.8 per 1,000 people every year. Admission to hospital is one of the main risk factors for VTE, and could account for up to 20% of all VTE, making VTE prevention in admitted patients an appealing option to reduce VTE global burden. ...

Phase

3.36 miles

Learn More »

An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

The Ependymoma Program is a comprehensive program to improve the accuracy of the primary diagnosis of ependymoma and explore different therapeutic strategies in children, adolescents and young adults, accordingly. This program is opened to all patients diagnosed with ependymoma below the age of 22 years. It will include a centralised ...

Phase

3.36 miles

Learn More »

EPIPAGE2 Cohort Study Follow up at Five and a Half Years

Epipage 2 (epidemiologic study on small-for-gestational-age children) is a nationwide study implemented to improve our knowledge of the outcome of preterm children in France. This study was launched on March 28, 2011 and includes three groups of preterm children, all born before 35 weeks: extremely preterm infants (born between 22 ...

Phase N/A

3.36 miles

Learn More »

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Patients will receive a single administration of NBTXR3 on day 1, either as an intra-arterial or intratumor injection, followed by Intensity Modulated Radiation Therapy starting 24 hours later (day 2), and up to completion of 7 weeks, i.e. 70 Grays, 2Grays/fraction. Patients whose tumor has completely shrunk will be followed ...

Phase

3.36 miles

Learn More »